We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-4.35%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$222M
AUM Growth
–
Cap. Flow
+$226M
Cap. Flow %
102.02%
Top 10 Hldgs %
61.86%
Holding
49
New
49
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$20.2M
2
BIIB icon
Biogen
BIIB
+$19.5M
3
SHPG
Shire pic
SHPG
+$16.9M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$16.4M
5
GILD icon
Gilead Sciences
GILD
+$13.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGYP
26
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.9M 0.86%
+312,000
New +$1.63M
ALDR
27
DELISTED
Alder Biopharmaceuticals
ALDR
$1.66M 0.75%
+80,000
New +$2.08M
KITE
28
DELISTED
Kite Pharma, Inc.
KITE
$1.64M 0.74%
+36,500
New +$1.79M
NBIX icon
29
Neurocrine Biosciences
NBIX
$15.8B
$1.56M 0.7%
+40,264
New +$1.82M
ACAD icon
30
Acadia Pharmaceuticals
ACAD
$5.12B
$1.46M 0.66%
+50,458
New +$1.33M
NDRM
31
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.44M 0.65%
+65,000
New +$1.22M
HZNP
32
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.37M 0.62%
+85,000
New +$1.54M
DERM
33
DELISTED
Dermira, Inc.
DERM
$1.36M 0.61%
+45,000
New +$1.45M
XNCR icon
34
Xencor
XNCR
$2.15B
$1.26M 0.57%
+48,000
New +$1.15M
TRIL
35
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.25M 0.56%
+221,847
New +$2.21M
ASXC
36
DELISTED
Asensus Surgical, Inc.
ASXC
$1.16M 0.52%
+68,391
New +$1.4M
MGNX icon
37
MacroGenics
MGNX
$260M
$1.1M 0.5%
+54,000
New +$1.36M
IRWD icon
38
Ironwood Pharmaceuticals
IRWD
$701M
$903K 0.41%
+70,446
New +$890K
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$867K 0.39%
+16,996
New +$801K
GWPH
40
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$838K 0.38%
+7,500
New +$903K
RDUS
41
DELISTED
Radius Health, Inc.
RDUS
$753K 0.34%
+19,799
New +$942K
NKTR icon
42
Nektar Therapeutics
NKTR
$2.55B
$736K 0.33%
+4,000
New +$813K
SRPT icon
43
Sarepta Therapeutics
SRPT
$2.28B
$576K 0.26%
+21,000
New +$843K
HALO icon
44
Halozyme
HALO
$12.1B
$572K 0.26%
+58,000
New +$635K
ARRY
45
DELISTED
Array Biopharma Inc
ARRY
$571K 0.26%
+65,000
New +$478K
XLRN
46
DELISTED
Acceleron Pharma
XLRN
$475K 0.21%
+18,606
New +$590K
ACOR
47
DELISTED
Acorda Therapeutics
ACOR
$414K 0.19%
+183
New +$435K
ADAP
48
DELISTED
Adaptimmune Therapeutics
ADAP
$387K 0.17%
+96,419
New +$463K
FOLD
49
DELISTED
Amicus Therapeutics
FOLD
$273K 0.12%
+55,000
New +$381K
1
2

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2016 Portfolio in Review

Q4 2016 is the first quarter with a 13F filing on record for International Biotechnology Trust, which disclosed 49 positions worth $222M. Its ten largest holdings account for 62% of the portfolio.

Its largest position is Celgene Corp: 181,722 shares worth $21M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • International Biotechnology Trust's largest Q4 2016 buy was Celgene Corp: 181,722 shares worth $21M.
  • International Biotechnology Trust's ten largest holdings make up 62% of its $222M portfolio in Q4 2016.
  • International Biotechnology Trust disclosed 49 positions in Q4 2016, its first 13F filing on record.

Based on International Biotechnology Trust's 13F filing for Q4 2016, filed 2 Mar 2018.